SAN
DIEGO, Jan. 30, 2023 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a company developing medical
technology to treat cancer and life-threatening infectious
diseases, today announced that it has entered into an agreement
with NAMSA, a world leading MedTech Contract Research Organization
(CRO) offering global end-to-end development services to oversee
the company's clinical trials investigating the Hemopurifier,
Aethlon's immunotherapeutic device , for oncology indications.
Pursuant to the agreement, NAMSA will manage Aethlon's study of
the Hemopurifier for patients in the
United States and Australia
with various types of cancer tumors. It is anticipated the initial
clinical trials will begin in Australia.
"Aethlon is committed to progressing the clinical development of
the Hemopurifier," said Charles J.
Fisher, M.D., Chief Executive Officer of Aethlon Medical.
"NAMSA is a world class organization with significant experience
managing clinical studies. Aethlon plans to move quickly to
leverage this experience to advance our trials with the
Hemopurifier in cancer patients."
"We are extremely pleased that Aethlon selected NAMSA as their
strategic outsourcing partner for their clinical research program,"
stated Dr. Christophe Berthoux,
NAMSA CEO. "NAMSA's mission is to deliver best-in-class global
MedTech solutions, and with increasing demand to find trusted
outsourcing partners to accelerate efficient clinical development
of life-changing medical products, we are well positioned to work
collaboratively with Aethlon," Dr. Berthoux concluded.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on
developing products to treat cancer and life threatening infectious
diseases. The Hemopurifier is Aethlon's clinical stage
immunotherapeutic device designed to combat cancer and
life-threatening viral infections. In human studies, the
Hemopurifier has demonstrated the removal of life-threatening
viruses and harmful exosomes from blood, utilizing a proprietary
lectin-based technology. This action has potential
applications in cancer, where exosomes may promote immune
suppression and metastasis, and in life-threatening infectious
diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA)
designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease.
The Hemopurifier also holds an FDA Breakthrough Device
designation and an open IDE application related to the treatment of
life-threatening viruses that are not addressed with approved
therapies.
Additional information can be found at
www.AethlonMedical.com.
ABOUT NAMSA
Helping medical device Sponsors improve healthcare since 1967,
NAMSA is the world's leading MedTech Contract Research Organization
(CRO) offering global end-to-end development services. Driven by
its global regulatory expertise and in-depth therapeutic knowledge,
NAMSA is dedicated to accelerating medical device product
development, offering only the most proven solutions to move
clients' products through the development lifecycle efficiently and
cost-effectively. From medical device testing; regulatory,
reimbursement and quality consulting; and clinical research
services, NAMSA is the industry's premier, trusted partner for
successful development and commercialization outcomes. Web:
namsa.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect," "intend," "plan," "project,"
"will," "projections," "estimate," "potentially" or similar
expressions constitute forward-looking statements. Such
forward-looking statements are subject to significant risks and
uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. These
forward-looking statements are based upon Aethlon's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's dependence
upon NAMSA to manage its clinical trials under the Master Services
Agreement between the parties, the Company's ability to enroll
patients in and successfully its complete trials in cancer patients
in Australia and the U.S., the
Company's ability to successfully complete development of its
Hemopurifier, and other potential risks. The foregoing list of
risks and uncertainties is illustrative, but is not exhaustive.
Additional factors that could cause results to differ materially
from those anticipated in forward-looking statements can be found
under the caption "Risk Factors" in the Company's Annual Report on
Form 10-K for the year ended March 31,
2022, and in the Company's other filings with the Securities
and Exchange Commission, including its quarterly Reports on Form
10-Q. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Except
as may be required by law, the Company does not intend, nor does it
undertake any duty, to update this information to reflect future
events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
NAMSA Media Contact
Leah Davidson, MA, MBA
Sr. Manager, Global Marketing Communications
Email: ldavidson@namsa.com
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-contract-with-namsa-to-advance-hemopurifier-clinical-programs-in-cancer-301732638.html
SOURCE Aethlon Medical, Inc.